We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00825812
First Posted: January 21, 2009
Last Update Posted: November 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
Results First Submitted: July 22, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Anesthesia, General
Neuromuscular Blockade
Interventions: Drug: Sugammadex
Drug: neostigmine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
308 participants were randomized

Reporting Groups
  Description
Sugammadex in Caucasian Subjects At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
Neostigmine in Caucasian Subjects At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
Sugammadex in Chinese Subjects At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
Neostigmine in Chinese Subjects At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.

Participant Flow:   Overall Study
    Sugammadex in Caucasian Subjects   Neostigmine in Caucasian Subjects   Sugammadex in Chinese Subjects   Neostigmine in Chinese Subjects
STARTED   29   32   126   121 
TREATED   29   31   120   111 
COMPLETED   29   31   120   111 
NOT COMPLETED   0   1   6   10 
Never entered follow up                0                0                0                1 
Adverse Event                0                0                0                1 
Subject withdrew consent                0                0                3                2 
Non-compliance with protocol                0                0                0                1 
Administrative                0                1                3                5 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sugammadex in Caucasian Subjects At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
Neostigmine in Caucasian Subjects At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
Sugammadex in Chinese Subjects At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
Neostigmine in Chinese Subjects At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
Total Total of all reporting groups

Baseline Measures
   Sugammadex in Caucasian Subjects   Neostigmine in Caucasian Subjects   Sugammadex in Chinese Subjects   Neostigmine in Chinese Subjects   Total 
Overall Participants Analyzed 
[Units: Participants]
 29   31   120   111   291 
Age 
[Units: Years]
Mean (Full Range)
 52.0 
 (27 to 64) 
 51.9 
 (34 to 63) 
 39.9 
 (19 to 63) 
 39.4 
 (18 to 61) 
 42.2 
 (18 to 64) 
Gender 
[Units: Participants]
         
Female   25   28   78   86   217 
Male   4   3   42   25   74 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.   [ Time Frame: start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade ]

2.  Secondary:   Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7 and 0.8.   [ Time Frame: start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp.
e-mail: ClinicalTrialsDisclosure@merck.com


Publications of Results:

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00825812     History of Changes
Other Study ID Numbers: P05768
19.4.324
First Submitted: January 15, 2009
First Posted: January 21, 2009
Results First Submitted: July 22, 2011
Results First Posted: August 18, 2011
Last Update Posted: November 2, 2015



To Top